Neurizon issues shares for investor relations as it advances ALS-focused pipeline

Pharmaust Limited ( (AU:NUZ) ) has shared an announcement.

Neurizon Therapeutics has issued 750,000 fully paid ordinary shares at a deemed price of $0.137 per share as part consideration for investor relations and strategic communications advisory services. The move modestly expands the company’s share base while underscoring its focus on strengthening investor outreach and market communication as it advances its neurodegenerative disease pipeline.

The company confirmed the shares were issued without a full prospectus under relevant Corporations Act provisions and that it remains compliant with its continuous disclosure and financial reporting obligations. Neurizon also stated there is no excluded information that would need to be disclosed to support secondary trading of these shares, aiming to provide regulatory clarity and maintain confidence among investors and other stakeholders.

The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.

More about Pharmaust Limited

Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), with a strategy to accelerate patient access while exploring broader neurodegenerative indications through international collaborations and clinical programs.

Average Trading Volume: 595,506

Technical Sentiment Signal: Sell

Current Market Cap: A$55.94M

For an in-depth examination of NUZ stock, go to TipRanks’ Overview page.